Se-Jin Jeong

Se-Jin Jeong

Auto-generated profile, based on publicly available information

Se-Jin Jeong

Division of Disease Control Research Planning, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2024 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
DKDong-Hwi Kim
Dong-Hwi Kim
MYMin-Gyu Yoo
Min-Gyu Yoo
NKNa-Young Kim
Na-Young Kim
SCSo Young Choi
So Young Choi
MJMinjeong Jang
Minjeong Jang
JKJungyeon Kim
Jungyeon Kim
Objectives: This study was conducted to assess the efficacy of nirmatrelvir/ritonavir treatment in patients with coronavirus disease 2019 (COVID-19), particularly those aged 60 years and older. Using real-world data, the period during which the BN.1 Omicron variant was dominant was compared to the period dominated by the BA.5 variant.Methods: In this retrospective cohort study, data were collected regarding 2,665,281 patients infected with severe acute respiratory syndrome coronavirus 2 between July 24, 2022, and March 31, 2023. Propensity score matching was utilized to match patients who received nirmatrelvir/ritonavir in a 1:4 ratio between BN.1 and BA.5 variant groups. Multivariable logistic regression analysis was employed to assess the effects of nirmatrelvir/ritonavir within these groups.Results: Compared to the prior period, the efficacy of nirmatrelvir/ritonavir did not significantly differ during the interval of Omicron BN.1 variant dominance in the Republic of Korea. Among patients treated with nirmatrelvir/ritonavir, a significantly lower risk of mortality was observed in the BN.1 group (odds ratio [OR], 0.698; 95% confidence interval [CI], 0.557–0.875) compared to the BA.5 group. However, this treatment did not significantly reduce the risk of severe or critical illness, including death, for those in the BN.1 group (OR, 0.856; 95% CI, 0.728–1.007).Conclusion: Nirmatrelvir/ritonavir has maintained its effectiveness against COVID-19, even with the emergence of the BN.1 Omicron subvariant. Consequently, we strongly recommend the administration of nirmatrelvir/ritonavir to patients exhibiting COVID-19-related symptoms, irrespective of the dominant Omicron variant or their vaccination status, to mitigate disease severity and decrease the risk of mortality.

31 August 2023 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
JJJin-Hwan Jeon
Jin-Hwan Jeon
SKSu Jin Kang
Su Jin Kang
SJSe-Jin Jeong
Se-Jin Jeong
HJHyeon-Cheol Jang
Hyeon-Cheol Jang
YPYoung-Joon Park
Young-Joon Park
SLSang Eun Lee
Sang Eun Lee
Objectives: This study aimed to examine the scale, characteristics, risk factors, and modes of transmission in a coronavirus disease 2019 (COVID-19) outbreak at a high school in Seoul, Republic of Korea.Methods: An epidemiological survey was conducted of 1,118 confirmed cases and close contacts from a COVID-19 outbreak at an educational facility starting on May 31, 2021. In-depth interviews, online questionnaires, flow evaluations, and CCTV analyses were used to devise infection prevention measures. Behavioral and spatial risk factors were identified, and statistical significance was tested.Results: Among 3rd-year students, there were 33 confirmed COVID-19 cases (9.6%). Students who used a study room in the annex building showed a statistically significant 4.3-fold elevation in their relative risk for infection compared to those who did not use the study room. Moreover, CCTV facial recognition analysis confirmed that 17.8% of 3rd-year students did not wear masks and had the lowest percentage of mask-wearers by grade. The air epidemiological survey conducted in the study room in the annex, which met the 3 criteria for a closed space, confirmed that there was only 10% natural ventilation due to the poor ventilation system.Conclusion: To prevent and manage the spread of COVID-19 in educational facilities, advance measures that consider the size, operation, and resources of each school are crucial. In addition, various survey methodologies should be used in future studies to quickly analyze a wider range of data that can inform an evidence-based quarantine response.

1 January 2025 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YCYou-Jung Choi
You-Jung Choi
LKLan Hee Kim
Lan Hee Kim
JJJinhwa Jang
Jinhwa Jang
SPShin Young Park
Shin Young Park
SJSejin Jeong
Sejin Jeong
SKSeong-Sun Kim
Seong-Sun Kim
Choi YJ, et al. J Korean Med Sci. 2025 Jun;40:e94. https://doi.org/10.3346/jkms.2025.40.e94

28 February 2025 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
SJSe-Jin Jeong
Se-Jin Jeong
SPShin Young Park
Shin Young Park
BRBoyeong Ryu
Boyeong Ryu
MAMisuk An
Misuk An
JJJin-Hwan Jeon
Jin-Hwan Jeon
SKSeong-Sun Kim
Seong-Sun Kim
Objectives: We analyzed the demographic and clinical characteristics of patients diagnosed with coronavirus disease 2019 (COVID-19), focusing specifically on severe/critical cases, and assessed the trends and rates of severity and fatality among these patients in the Republic of Korea.Methods: Clinical data on patients with COVID-19 from January 20, 2020 to August 30, 2023 were collected from the Korea Disease Control and Prevention Agency’s database. We identified patients who progressed to severe/critical conditions and analyzed their demographic and clinical profiles. Severity and fatality rates were calculated and compared annually to track the disease progression over time.Results: During the surveillance period, 34,572,554 COVID-19 cases were confirmed, among whom 38,112 (0.11%) progressed to severe/critical conditions. Most severe/critical cases occurred in individuals aged ≥60 years, with a notable increase in patients aged ≥80 years from 2022. The overall severity rate was 0.19%, with a fatality rate of 0.10%. However, the severity of cases gradually diminished during the study period. In 2022, the severity and fatality rates decreased to 0.14% and 0.09%, respectively. In 2023, while the severity rate remained stable at 0.15%, the fatality rate further decreased to 0.06%. Notably, throughout the study period, individuals aged ≥80 years had a significantly higher severity rate (2.44%), with a fatality rate of 1.75%.Conclusion: These findings underscore the importance of prioritizing protection and management strategies for older adults and high-risk groups to mitigate the impact of COVID-19. Continued surveillance and analysis are essential to effectively control COVID-19 and minimize its burden on public health.

14 May 2026 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
JCJong-Hoon Choi
Jong-Hoon Choi
SHSung-Hee Hong
Sung-Hee Hong
CKCha-Yoon Kim
Cha-Yoon Kim
JKJi-Young Kwon
Ji-Young Kwon
JSJi Ye Seo
Ji Ye Seo
HLHee Il Lee
Hee Il Lee
Osong Public Health and Research Perspectives